A Randomised, Multi-Centre, Assessor-Blinded, Active-Controlled, Parallel Group, Equivalence Phase III Study Comparing the Safety and Efficacy of USV Pegfilgrastim and Neulasta in Breast Cancer Patients Undergoing Myelosuppressive Chemotherapy

Trial Profile

A Randomised, Multi-Centre, Assessor-Blinded, Active-Controlled, Parallel Group, Equivalence Phase III Study Comparing the Safety and Efficacy of USV Pegfilgrastim and Neulasta in Breast Cancer Patients Undergoing Myelosuppressive Chemotherapy

Recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Jun 2017

At a glance

  • Drugs Pegfilgrastim (Primary)
  • Indications Febrile neutropenia; Neutropenia
  • Focus Registrational; Therapeutic Use
  • Sponsors USV
  • Most Recent Events

    • 17 Jun 2017 This trial has been completed in Hungary (end date: 21 Feb 2017).
    • 28 May 2017 This trial has been completed in Bulgaria (end date: 21 Feb 2017).
    • 04 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top